CINECA IRIS Institutional Research Information System

SISMONDI, Piero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.029
EU - Europa 7.496
AS - Asia 3.359
AF - Africa 69
Continente sconosciuto - Info sul continente non disponibili 12
SA - Sud America 10
OC - Oceania 9
Totale 18.984
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.863
CN - Cina 2.170
IE - Irlanda 1.128
UA - Ucraina 1.081
IT - Italia 1.021
DE - Germania 982
SE - Svezia 899
FR - Francia 707
FI - Finlandia 651
KR - Corea 633
GB - Regno Unito 555
SG - Singapore 345
PL - Polonia 279
CA - Canada 164
VN - Vietnam 130
AT - Austria 91
IN - India 37
SN - Senegal 36
MU - Mauritius 26
NL - Olanda 24
BE - Belgio 23
GR - Grecia 14
PH - Filippine 12
EU - Europa 11
RU - Federazione Russa 10
JP - Giappone 9
BR - Brasile 8
ES - Italia 8
AU - Australia 7
CH - Svizzera 6
RO - Romania 6
TR - Turchia 5
IR - Iran 4
IL - Israele 3
PT - Portogallo 3
QA - Qatar 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
EG - Egitto 2
HU - Ungheria 2
MX - Messico 2
NZ - Nuova Zelanda 2
UG - Uganda 2
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
HK - Hong Kong 1
HR - Croazia 1
ID - Indonesia 1
IS - Islanda 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
TW - Taiwan 1
Totale 18.984
Salva come PNG Salva come JPEG
Città #
Beijing 1.906
Houston 1.231
Chandler 1.178
Dublin 1.127
Jacksonville 660
Medford 460
Princeton 428
Villeurbanne 399
Ann Arbor 312
Milan 307
Warsaw 275
Dearborn 215
Singapore 207
Wilmington 186
Verona 173
Nyköping 158
Woodbridge 147
Ashburn 128
Boardman 113
Boston 97
Fairfield 95
Vienna 89
Toronto 79
Dong Ket 78
Torino 77
Lachine 74
Norwalk 70
Fremont 55
Falls Church 52
Düsseldorf 44
Menlo Park 36
Seattle 34
Hefei 33
Cambridge 30
Guangzhou 29
Nanjing 27
Rome 25
Brussels 22
Nanchang 19
New York 19
Redwood City 19
Birmingham 18
Pisa 18
Turin 17
Naples 16
Redmond 16
Athens 14
Kunming 14
Shenyang 14
Jinan 13
Munich 13
Zhengzhou 13
Bari 11
Fuzhou 11
Los Angeles 11
Mountain View 11
Florence 10
Hebei 10
Detroit 9
Pune 9
Shenzhen 8
Palermo 7
Tappahannock 7
Shanghai 6
Tokyo 6
Wuhan 6
Chengdu 5
Hangzhou 5
Ottawa 5
Philadelphia 5
Phoenix 5
San Mateo 5
Washington 5
Amsterdam 4
Barletta 4
Bologna 4
Changchun 4
Finale Ligure 4
Livorno 4
Mascalucia 4
Nürnberg 4
Piemonte 4
Prato 4
San Francisco 4
Aquila 3
Biancavilla 3
Changsha 3
Cinisello Balsamo 3
Como 3
Doha 3
Gonnosfanadiga 3
Helsinki 3
Izmir 3
Lecce 3
Manila 3
Montebello Jonico 3
North Bergen 3
Olongapo City 3
Piacenza 3
Pofi 3
Totale 11.128
Salva come PNG Salva come JPEG
Nome #
Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. 305
Chemoprevention or mastectomy for women at high risk of developing breast cancer 291
Anatomia della mammella 208
Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population 191
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer 169
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion 154
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. 149
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment 143
Effetti dei progestinici sul rischio mammario. 142
Terapia pulsatile: nuova via o diverso approccio terapeutico? 141
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits 129
Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. 123
Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer 119
3rd TRAINING THE TRAINERS COURSE FOR EDUCATIONAL SUPERVISORS IN OBTETRICS AND GYNAECOLOGY 118
Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. 118
HRT and breast cancer risk: a clue for interpreting the available data. 117
Insulin-like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values. 113
[Postoperative infections and antibiotic prophylaxis in radical hysterectomy. Review of the literature] 112
[Postoperative infections and antibiotic prophylaxis in radical hysterectomy. Retrospective study] 106
Benign breast disease. An update. 103
Progestins and breast cancer risk. 102
A new technique to test tubal patency under transvaginal sonographic control. 101
How to manage the menopause following therapy for breast cancer. Is raloxifene a safe alternative? 98
AP-2{alpha} and AP-2{gamma} regulate tumor progression via specific genetic programs 97
The AP-2alpha and AP-2gamma transcription factors regulate tumor formation 97
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 95
TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. 93
Tamoxifen and endometrial cancer. 93
Comparison of two models for the prediction of nonsentinel node metastases in breast cancer 92
Conjugated estrogens and breast cancer risk. 91
Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience 91
HRT, breast and endometrial cancers: strategies and intervention options. 91
The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. 88
Chemoresistance in breast tumors. 88
The AP-2alpha transcription factor regulates tumor cell migration and apoptosis 86
The AP-2alpha and AP-2gamma transcription factors regulate tumor formation and progression via specific genetic programs 86
Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. 85
Transvaginal salpingo-sonography (TSSG) in the evaluation of tubal patency. 85
Critical review of the article by Colditz et al. on 'The use of estrogens and progestins and the risk of breast cancer in postmenopausal women' published in the N.E.J.M. 1995, 332: 1589. 84
Insulin-like growth factor-I and risk of breast cancer. 82
miR-148b is a major coordinator in a Relapse-associated miR signature in Breast Tumors. 82
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival 81
GnRH analogs in benign breast disease and breast cancer chemoprevention. A challenge for the year 2000. 80
[Bone marrow toxicity of the chemotherapy of gynecological tumors] 80
[Anatomo-pathological verification of dosimetry using a calculator in curietherapy of cancer of the cervix uteri] 80
Raloxifene and endometrial cancer. 79
Validation of different radioguided techniques for sentinel node localization in breast cancer patients. 79
AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase 79
Le lesioni preneoplastiche della mammella. 78
Ginecologia e Ostetricia 78
Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region 78
Oral contraceptive use and breast cancer risk in areas with different incidence. A case-control study among young women. 77
Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. 77
Metabolic effects of tamoxifen in postmenopause. 77
c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. 77
[Uterine microcirculation evaluated with Xe-133 in normal and pathological pregnancy] 76
microRNA and cancer progression in Breast Tumours 75
Oral contraceptives and breast cancer. 74
Identification of new genes associated with breast cancer progression by gene expression analysis of pre-defined sets of neoplastic tissues 74
Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging 74
Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. 73
Misplaced confidences? 73
Hormone replacement therapy and breast cancer risk. 73
Analysis of complications of cervix carcinoma treated by radiotherapy using the Franco-Italian glossary. 72
Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. 72
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes 72
Antiemetic efficacy of granisetron in patients with gynecological malignancies. 70
Pathological classification of ductal carcinoma in situ of the breast correlates with surgical treatment and may be predicted by mammography 70
Antihormones in prevention and treatment of breast cancer 70
Risk reducing surgery and treatment of menopausal symptoms in BRCA mutation carriers (and other risk women) 70
[Aspects of renal function in different ages of adulthood: clearances, tubular function and proximal and distal electrolyte reabsorption] 69
Transvaginal sonographic tubal patency testing using air and saline solution as contrast media in a routine infertility clinic setting. 69
Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity. 69
Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study 69
Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. 69
Transient ventricular hypocinesia after in utero anthracyclines exposure: a case-report and review of the literature. 68
[Urinary excretion of total neutral ketosteroids in the last trimester of pregnancy. II. Behavior in various cases of gestosis and comparison with estrogen excretion] 67
A survey on the menopause after breast cancer. 67
microRNAs and cancer progression in Breast Tumours 67
C-erb B2 and RAS expression levels in breast cancer. 67
Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. 67
[Bone marrow toxicity of chemotherapy combinations in operable carcinoma of the breast] 66
[Studies on cellular water-electrolyte metabolism in edematous states. Observations of edema due to hepatic cirrhosis] 66
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy 66
Benefit from anthracyclines in relation to biological profiles in early breast cancer. 66
[The use of isoxsuprine in the treatment of threatened abortion] 65
[STUDY OF (PROXIMAL AND DISTAL) RENAL TUBULAR FUNCTION IN EDEMATOUS STATES.] 65
Hormonal replacement therapy after gynaecological cancer 65
Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial 65
Behaviour of ovarian tumors of low malignant potential treated with conservative surgery 65
Antihormones in prevention and treatment of breast cancer. 65
[Breast carcinoma and pregnancy] 64
A glossary for reporting complications of treatment in gynecological cancers. 64
microRNA and cancer progression in Breast Tumours 64
Benign breast disease: mith and reality. 64
La patologia mammaria – Nuove tecniche chirurgiche conservative. 64
[The use of aminoglutethimide in the treatment of metastatic breast cancer] 63
[The acid-base equilibrium of the urine in normal pregnancy and in gestosis] 62
[Renal excretion and reabsorption (proximal and distal) of electrolytes in normal and pathological pregnancy] 62
Aromatase inhibitors for breast cancer: different structures, same effects? 62
Totale 9.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.042
article - articoli 0
book - libri 0
conference - conferenze 12.618
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.660
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.172 0 148 276 145 417 1.158 298 73 283 165 179 30
2020/20212.124 305 36 260 100 189 85 198 17 379 215 122 218
2021/20221.959 12 78 83 51 72 29 120 96 81 107 403 827
2022/20233.726 477 144 54 305 413 1.176 344 209 368 51 122 63
2023/20241.213 172 284 53 67 43 103 27 56 4 36 94 274
2024/202531 26 5 0 0 0 0 0 0 0 0 0 0
Totale 19.821